Lung Cancer Trial, Recruiting NCT07195084 Sponsor: Anhui Provincial Cancer Hospital Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT07195084
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older
  • People whose overall health and ability to carry out daily activities meets a certain minimum level, as measured by a standard scoring system called the Karnofsky Performance Status (score above 80) (confirm with trial site)
  • People who have been diagnosed with non-small cell lung cancer (NSCLC) — either confirmed through a tissue or cell sample, or diagnosed based on scan results and specialist team agreement when a tissue sample cannot safely be obtained
  • People whose tumor is classified as early-stage (small, no spread to lymph nodes or other parts of the body), based on CT and PET scan results, with the tumor being 3 cm or smaller
  • People whose tumor is located more than 2 cm away from the central airways of the lungs in all directions (confirm with trial site)
  • People whose lung function test results meet certain minimum levels — specifically, breathing capacity (FEV1) and gas exchange ability (DLCO) above set thresholds (confirm with trial site)
  • People who are able to undergo a PET-CT scan
  • Women of childbearing age who have had a negative pregnancy test within 7 days before the first study treatment

Who may not be able to join:

  • People who have had another type of cancer diagnosed within the past 2 years
  • People who have previously had radiotherapy to the chest
  • People who are planned to receive other cancer treatments at the same time as the trial treatment (within a 4-week window)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Shuanghu Yuan, PhD, Anhui Provincial Hospital

Phone: 0551-62894008

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Anhui Provincial Cancer Hospital
Registry
ClinicalTrials.gov
Start date
20 September 2025
Est. completion
19 September 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The incidence of grade ≥ 3 psAEs at 1 month; The incidence of grade ≥ 3 psAEs at 1 year

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov